State Street Corp reduced its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 26.7% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 30,955,079 shares of the medical research company’s stock after selling 11,250,164 shares during the quarter. State Street Corp owned about 0.06% of Amgen worth $13,047,875,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Cornerstone Select Advisors LLC increased its holdings in shares of Amgen by 4.8% in the third quarter. Cornerstone Select Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $2,096,000 after purchasing an additional 228 shares during the last quarter. Fort Sheridan Advisors LLC raised its position in shares of Amgen by 1.7% in the third quarter. Fort Sheridan Advisors LLC now owns 8,653 shares of the medical research company’s stock valued at $3,647,000 after purchasing an additional 148 shares during the period. E Fund Management Hong Kong Co. Ltd. lifted its stake in shares of Amgen by 52.3% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 4,763 shares of the medical research company’s stock worth $2,008,000 after buying an additional 1,636 shares during the last quarter. Sumitomo Life Insurance Co. lifted its stake in shares of Amgen by 1.2% during the 3rd quarter. Sumitomo Life Insurance Co. now owns 5,162 shares of the medical research company’s stock worth $2,176,000 after buying an additional 63 shares during the last quarter. Finally, FCA Corp TX lifted its stake in shares of Amgen by 2.2% during the 3rd quarter. FCA Corp TX now owns 16,602 shares of the medical research company’s stock worth $6,998,000 after buying an additional 357 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.
Amgen Trading Down 0.8%
Shares of Amgen stock opened at $435.52 on Friday. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.20 and a current ratio of 1.48. The firm has a 50-day moving average of $430.44 and a 200-day moving average of $383.81. Amgen Inc. has a 52-week low of $312.39 and a 52-week high of $483.99. The stock has a market cap of $235.58 billion, a PE ratio of 25.26, a PEG ratio of 3.22 and a beta of 0.43.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share for the quarter, topping the consensus estimate of $5.79 by $0.66. The business had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The business’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.64 EPS. As a group, sell-side analysts forecast that Amgen Inc. will post 23.41 EPS for the current year.
Amgen Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Stockholders of record on Friday, November 20th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s dividend payout ratio is 58.47%.
Analysts Set New Price Targets
Several brokerages recently commented on AMGN. Argus lifted their target price on shares of Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a report on Thursday, November 12th. Barclays increased their price target on shares of Amgen from $400.00 to $430.00 and gave the company an “equal weight” rating in a report on Monday, November 16th. Mizuho raised their price objective on shares of Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Jefferies Financial Group restated a “hold” rating and set a $410.00 price objective on shares of Amgen in a report on Wednesday, September 23rd. Finally, Wells Fargo & Company boosted their price objective on Amgen from $430.00 to $460.00 and gave the stock an “equal weight” rating in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $428.62.
View Our Latest Stock Report on AMGN
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Recommended Stories
- Five stocks we like better than Amgen
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
